Neovasc Inc. (TSE:NVC – Get Rating) (NASDAQ:NVCN) – Investment analysts at HC Wainwright cut their FY2022 earnings per share (EPS) estimates for shares of Neovasc in a report issued on Tuesday, November 15th. HC Wainwright analyst V. Bernardino now expects that the company will post earnings of ($14.95) per share for the year, down from their prior estimate of ($14.91). HC Wainwright also issued estimates for Neovasc’s Q4 2022 earnings at ($2.57) EPS and FY2023 earnings at ($11.20) EPS.
Neovasc Stock Performance
Neovasc has a 52 week low of C$0.49 and a 52 week high of C$6.07. The stock has a 50 day moving average of C$1.78.
Insiders Place Their Bets
In other news, Director Paul Geyer acquired 4,486 shares of the business’s stock in a transaction dated Friday, September 16th. The stock was acquired at an average price of C$8.39 per share, for a total transaction of C$37,615.11. Following the completion of the acquisition, the director now directly owns 4,486 shares in the company, valued at approximately C$37,615.11. In the last quarter, insiders acquired 11,757 shares of company stock worth $92,751.
Neovasc Inc (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products.
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
Receive News & Ratings for Neovasc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc and related companies with MarketBeat.com's FREE daily email newsletter.